Brief: RNAimmune Receives FDA Clearance Of Investigational New Drug Application For Phase 1 Trial Of RV-1730 COVID-19 Booster Vaccine
27/04/2023 18:40
April 27 (Reuters) - Sirnaomics Ltd 2257.HK :
* RNAIMMUNE RECEIVES FDA CLEARANCE OF INVESTIGATIONAL NEW
DRUG
APPLICATION FOR PHASE 1 TRIAL OF RV-1730 COVID-19 BOOSTER
VACCINE
Source text for Eikon: ID:nPnwv6fHa
Further company coverage: 2257.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sirnaomics
See all newsBrief: Sirnaomics To Issue 2.4 Million New Shares At Hk$4.69 Each Under General Mandate
Brief: Sirnaomics Says Chairman Purchases 38,000 Shares At Average Price Hk$5.93 Per Share
Brief: Sirnaomics Ltd To Issue 17.4 Million Subscription Shares
Brief: Sirnaomics Says Poon Hung Fai Appointed As Chairman
Brief: Sirnaomics Posts FY Net Income USD -50.2 Million